Sepsis and ARDS: The Dark Side of Histones

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Xu, Zhiheng ^a   Huang, Yongbo ^a   Mao, Pu ^a   Zhang, Jianrong ^a   Li, Yimin ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; CRYOPYRIN; HISTONE; INFLAMMASOME; RECOMBINANT THROMBOMODULIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; CARRIER PROTEIN; NLRP3 PROTEIN, HUMAN; TOLL LIKE RECEPTOR;

ADULT RESPIRATORY DISTRESS SYNDROME; BLOOD CLOTTING; CELL DEATH; CYTOTOXICITY; EXTRACELLULAR MATRIX; EXTRACELLULAR TRAP; HUMAN; IMMUNOSTIMULATION; LUNG FLUID; MEMBRANE PERMEABILITY; NONHUMAN; PATHOGENESIS; PLASMA; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN TARGETING; REVIEW; SEPSIS; THROMBOSIS; INFLAMMATION; PHYSIOLOGY; RESPIRATORY DISTRESS SYNDROME, ADULT;

CARRIER PROTEINS; EXTRACELLULAR TRAPS; HISTONES; HUMANS; INFLAMMATION; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; RESPIRATORY DISTRESS SYNDROME, ADULT; SEPSIS; THROMBOSIS; TOLL-LIKE RECEPTORS;

EID: 84947217955     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/205054     Document Type: Review

References (72)

1. C. Brun-Buisson, P.Meshaka, P. Pinton, and B. Vallet, "EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units," Intensive Care Medicine, vol. 30, no. 4, pp. 580-588, 2004.
2. D. F. Gaieski, J. M. Edwards, M. J. Kallan, and B. G. Carr, "Benchmarking the incidence and mortality of severe sepsis in the united states," Critical CareMedicine, vol. 41, no. 5, pp. 1167-1174, 2013.
3. A. D. Bersten, C. Edibam, T. Hunt, and J. Moran, "Incidence and mortality of acute lung injury and the acute respiratory distress syndrome in three Australian States," American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 4, pp. 443-448, 2002.
4. B. L. Warren, A. Eid, P. Singer et al., "High-dose antithrombin III in severe sepsis: a randomized controlled trial," Journal of the American Medical Association, vol. 286, no. 15, pp. 1869-1878, 2001.
5. E. Abraham, K. Reinhart, S. Opal et al., "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial,"The Journal of the AmericanMedical Association, vol. 290, no. 2,pp. 238-247, 2003.
6. D. Annane, P. Vignon, A. Renault et al., "Norepinephrine plus dobutamine versus epinephrine alone formanagement of septic shock: a randomised trial," The Lancet, vol. 370, no. 9588, pp. 676-684, 2007.
7. J. A. Russell, K. R. Walley, J. Singer et al., "Vasopressin versus norepinephrine infusion in patients with septic shock,"TheNew England Journal of Medicine, vol. 358, no. 9, pp. 877-887, 2008.
8. E. Abraham, P.-F. Laterre, R. Garg et al., "Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death," The New England Journal of Medicine, vol. 353, no. 13, pp. 1332-1341, 2005.
9. A. Esteban, F. Frutos-Vivar,A.Muriel et al., "Evolution of mortality over time in patients receiving mechanical ventilation," The American Journal of Respiratory and Critical CareMedicine, vol. 188, no. 2, pp. 220-230, 2013.
10. K.-M. Kaukonen, M. Bailey, S. Suzuki, D. Pilcher, and R. Bellomo, "Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012," The Journal of the American Medical Association, vol. 311, no. 13, pp. 1308-1316, 2014.
11. G. Kumar, N. Kumar, A. Taneja et al., "Nationwide trends of severe sepsis in the 21st century (2000-2007)," Chest, vol. 140, no. 5, pp. 1223-1231, 2011.
12. J. Villar, J. Blanco, J. M. Ãńon et al., "The ALIEN study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation," Intensive Care Medicine, vol. 37, no. 12, pp. 1932-1941, 2011.
13. M. A. Matthay and R. L. Zemans, "The acute respiratory distress syndrome: pathogenesis and treatment," Annual Review of Pathology, vol. 6, pp. 147-163, 2011.
14. D. C. Angus and T. van der Poll, "Severe sepsis and septic shock," The New England Journal of Medicine, vol. 369, no. 9, pp. 840-851, 2013.
15. M. A. Matthay, L. B. Ware, and G. A. Zimmerman, "The acute respiratory distress syndrome,"The Journal of Clinical Investigation, vol. 122, no. 8, pp. 2731-2740, 2012.
16. J.Xu, X. Zhang, R. Pelayoet al., "Extracellularhistones aremajor mediators of death in sepsis," Nature Medicine, vol. 15, no. 11, pp. 1318-1321, 2009.
17. M. L. Ekaney, G. P. Otto, M. Sossdorf et al., "Impact of plasma histones in human sepsis and their contribution to cellular injury and inflammation," Critical Care, vol. 18, no. 5, p. 543, 2014.
18. S. T. Abrams, N. Zhang, J. Manson et al., "Circulating histones are mediators of trauma-associated lung injury," American Journal of Respiratory and Critical CareMedicine, vol. 187, no. 2, pp. 160-169, 2013.
19. Y. Zhang, Z.Wen, L. Guan et al., "Extracellular histones play an inflammatory role in acid aspiration-induced acute respiratory distress syndrome," Anesthesiology, vol. 122, no. 1, pp. 127-139, 2015.
20. G. Felsenfeld and M. Groudine, "Controlling the double helix," Nature, vol. 421, no. 6921, pp. 448-453, 2003.
21. R.Chen, R. Kang,X.-G. Fan, andD.Tang, "Release and activity of histone in diseases," Cell Death and Disease, vol. 5, no. 8, Article ID e1370, 2014.
22. D. S. Pisetsky, "The translocation of nuclear molecules during inflammation and cell death," Antioxidants and Redox Signaling, vol. 20, no. 7, pp. 1117-1125, 2014.
23. A. J. Andrews and K. Luger, "Nucleosome structure(s) and stability: variations on a theme," Annual Review of Biophysics, vol. 40, no. 1, pp. 99-117, 2011.
24. W.Hou,Q. Zhang, Z. Yan et al., "Strange attractors:DAMPs and autophagy link tumor cell death and immunity," Cell Death and Disease, vol. 4, no. 12, article e966, 2013.
25. D. Tang, R. Kang, C. B. Coyne, H. J. Zeh, and M. T. Lotze, "PAMPs and DAMPs: signal 0s that spur autophagy and immunity," Immunological Reviews, vol. 249, no. 1, pp. 158-175, 2012.
26. Q.Zhang,R.Kang, H. J. Zeh,M. T. Lotze, andD.Tang, "DAMPs and autophagy: cellular adaptation to injury and unscheduled cell death," Autophagy, vol. 9, no. 4, pp. 451-458, 2013.
27. H. Zhang, J. Villar, and A. S. Slutsky, "Circulating histones: a novel target in acute respiratory distress syndrome?" American Journal of Respiratory and Critical CareMedicine, vol. 187, no. 2, pp. 118-120, 2013.
28. C. Chaput and A. Zychlinsky, "Sepsis: the dark side of histones," Nature Medicine, vol. 15, no. 11, pp. 1245-1246, 2009.
29. D. L. Rosin and M. D. Okusa, "Dying cells and extracellular histones in AKI: beyond a NET effect?" Journal of the American Society of Nephrology, vol. 23, no. 8, pp. 1275-1277, 2012.
30. R. Allam, C. R. Scherbaum, M. N. Darisipudi et al., "Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4," Journal of the American Society of Nephrology, vol. 23, no. 8, pp. 1375-1388, 2012.
31. R. S. Hotchkiss, A. Strasser, J. E. McDunn, and P. E. Swanson, "Mechanisms of disease: cell death," The New England Journal of Medicine, vol. 361, no. 16, pp. 1570-1583, 2009.
32. G. R.Wickman, L. Julian, K.Mardilovich et al., "Blebs produced by actin-myosin contraction during apoptosis release damageassociated molecular pattern proteins before secondary necrosis occurs," Cell Death and Differentiation, vol. 20, no. 10, pp. 1293-1305, 2013.
33. D.Wu,A. Ingram, J.H.Lahti et al., "Apoptotic releaseof histones fromnucleosomes,"The Journal of Biological Chemistry, vol. 277, no. 14, pp. 12001-12008, 2002.
34. V. Brinkmann, U. Reichard, C. Goosmann et al., "Neutrophil extracellular traps kill bacteria," Science, vol. 303, no. 5663, pp. 1532-1535, 2004.
35. M. Saffarzadeh, C. Juenemann, M. A. Queisser et al., "Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones," PLoS ONE, vol. 7, no. 2,Article ID e32366, 2012.
36. N. Semeraro, C. T. Ammollo, F. Semeraro, andM. Colucci, "Sepsis, thrombosis and organ dysfunction," Thrombosis Research, vol. 129, no. 3, pp. 290-295, 2012.
37. H. Huang, J. Evankovich, W. Yan et al., "Endogenous histones function as alarmins in sterile inflammatory liver injury through Toll-like receptor 9 in mice," Hepatology, vol. 54, no. 3, pp. 999-1008, 2011.
38. J. Xu, X. Zhang, M. Monestier, N. L. Esmon, and C. T. Esmon, "Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury," Journal of Immunology, vol. 187, no. 5, pp. 2626-2631, 2011.
39. F. Semeraro, C. T. Ammollo, J. H. Morrissey et al., "Extracellular histones promote thrombin generation through plateletdependent mechanisms: Involvement of platelet TLR2 and TLR4," Blood, vol. 118, no. 7, pp. 1952-1961, 2011.
40. "American College of Chest Physicians/Society of Critical Care Medicine Consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis," Critical Care Medicine, vol. 20, no. 6, pp. 864-874, 1992.
41. P. E. Marik, "Surviving sepsis: going beyond the guidelines," Annals of Intensive Care, vol. 1, article 17, 2011.
42. M. Bosmann, J. J. Grailer, R. Ruemmler et al., "Extracellular histones are essential effectors of C5aR-and C5L2-mediated tissue damage and inflammation in acute lung injury," The FASEB Journal, vol. 27, no. 12, pp. 5010-5021, 2013.
43. Y. Alhamdi, S. T. Abrams, Z. Cheng et al., "Circulating histones are major mediators of cardiac injury in patients with sepsis," Critical Care Medicine, 2015.
44. A. Pini, J. D. Gilthorpe, F. Oozeer et al., "Extracellular histone H1 is neurotoxic and drives a pro-inflammatory response in microglia," F1000Research, vol. 2, article 148, 2013.
45. D. S. Pisetsky, "Immune activation by histones: plusses and minuses in inflammation," European Journal of Immunology, vol. 43, no. 12, pp. 3163-3166, 2013.
46. T. J.Kleine, A. Gladfelter,P.N. Lewis, and S. A. Lewis, "Histoneinduced damage of a mammalian epithelium: the conductive effect,"TheAmerican Journal of Physiology-Cell Physiology, vol. 268, no. 5, part 1, pp. C1114-C1125, 1995.
47. T. J. Kleine, P. N. Lewis, and S. A. Lewis, "Histone-induced damage of a mammalian epithelium: the role of protein and membrane structure," The American Journal of Physiology-Cell Physiology, vol. 273, no. 6, pp. C1925-C1936, 1997.
48. V. Ganapathy and C. S. S. Devi, "Effect of histone H1 on the cytosolic calcium levels in human breast cancer MCF 7 cells," Life Sciences, vol. 76, no. 22, pp. 2631-2641, 2005.
49. A. Gamberucci, R. Fulceri, P. Marcolongo, W. F. Pralong, and A. Benedetti, "Histones and basic polypeptides activate Ca2+/ cation influx in various cell types," Biochemical Journal, vol. 331, no. 2, pp. 623-630, 1998.
50. Z.-G. Liu, S.-Y. Ni, G.-M. Chen et al., "Histones-mediated lymphocyte apoptosis during sepsis is dependent on p38 phosphorylation and mitochondrial permeability transition," PLoS ONE, vol. 8, no. 10, Article IDe77131, 2013.
51. L. Raffray, I. Douchet, J.-F. Augusto et al., "Septic shock sera containing circulating histones induce dendritic cell-regulated necrosis in fatal septic shock patients," Critical Care Medicine, vol. 43, no. 4, pp. e107-e116, 2015.
52. M. Aziz, A. Jacob,W.-L. Yang, A. Matsuda, and P.Wang, "Current trends in inflammatory and immunomodulatory mediators in sepsis," Journal of Leukocyte Biology, vol. 93, no. 3, pp. 329-342, 2013.
53. J. K. Chan, J. Roth, J. J. Oppenheim et al., "Alarmins: awaiting a clinical response,"The Journal of Clinical Investigation, vol. 122, no. 8, pp. 2711-2719, 2012.
54. R. Allam, S. V. R. Kumar, M. N. Darisipudi, and H.-J. Anders, "Extracellular histones in tissue injury and inflammation," Journal of Molecular Medicine, vol. 92, no. 5, pp. 465-472, 2014.
55. H. Hemmi, O. Takeuchi, T. Kawai et al., "A Toll-like receptor recognizes bacterial DNA," Nature, vol. 408, no. 6813, pp. 740-745, 2000.
56. J. Tian, A. M. Avalos, S.-Y. Mao et al., "Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE," Nature Immunology, vol. 8, no. 5, pp. 487-496, 2007.
57. R. Allam, M. N. Darisipudi, J. Tschopp, and H.-J. Anders, "Histones trigger sterile inflammation by activating the NLRP3 inflammasome," European Journal of Immunology, vol. 43, no. 12, pp. 3336-3342, 2013.
58. H. Huang, H.-W. Chen, J. Evankovich et al., "Histones activate theNLRP3 inflammasomeinKupffer cells during sterile inflammatory liver injury," Journal of Immunology, vol. 191, no. 5, pp. 2665-2679, 2013.
59. J. J. Grailer, B. A. Canning, M. Kalbitz et al., "Critical role for the NLRP3 inflammasome during acute lung injury," Journal of Immunology, vol. 192, no. 12, pp. 5974-5983, 2014.
60. M. Kalbitz, J. J. Grailer, F. Fattahi et al., "Role of extracellular histones in the cardiomyopathy of sepsis," The FASEB Journal, vol. 29, no. 5, pp. 2185-2193, 2015.
61. P. Dinarvand, S. M. Hassanian, S. H. Qureshi et al., "Polyphosphate amplifies proinflammatory responses of nuclear proteins through interaction with receptor for advanced glycation end products and P2Y1 purinergic receptor," Blood, vol. 123, no. 6, pp. 935-945, 2014.
62. M. Levi, M. Schultz, and T. van der Poll, "Disseminated intravascular coagulation in infectious disease," Seminars in Thrombosis and Hemostasis, vol. 36, no. 4, pp. 367-377, 2010.
63. N. Semeraro, C. T. Ammollo, F. Semeraro, and M. Colucci, "Sepsis-associated disseminated intravascular coagulation and thromboembolic disease,"Mediterranean Journal ofHematology and Infectious Diseases, vol. 2, no. 3, Article ID e2010024, 2010.
64. K.Martinod,M. Demers, T. A. Fuchs et al., "Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 21, pp. 8674-8679, 2013.
65. T. A. Fuchs, A. A. Bhandari, andD.D.Wagner, "Histones induce rapid and profound thrombocytopenia in mice," Blood, vol. 118, no. 13, pp. 3708-3714, 2011.
66. F.W. Lam, M. A. Cruz,H.-C. E. Leung, K. S. Parikh,C.W. Smith, and R. E. Rumbaut, "Histone induced platelet aggregation is inhibited by normal albumin," Thrombosis Research, vol. 132, no. 1, pp. 69-76, 2013.
67. A. Carestia, L. Rivadeneyra, M. A. Romaniuk, C. Fondevila, S. Negrotto, and M. Schattner, "Functional responses and molecular mechanisms involved in histone-mediated platelet activation," Thrombosis and Haemostasis, vol. 110, no. 5, pp. 1035-1045, 2013.
68. M. Nakahara, T. Ito, K.-I. Kawahara et al., "Recombinant thrombomodulin protects mice against histone-induced lethal thromboembolism," PLoS ONE, vol. 8, no. 9,Article ID e75961, 2013.
69. C. T. Esmon, "Extracellular histones zap platelets," Blood, vol. 118, no. 13, pp. 3456-3457, 2011.
70. C. T. Ammollo, F. Semeraro, J. Xu, N. L. Esmon, and C. T. Esmon, "Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation," Journal ofThrombosis and Haemostasis, vol. 9, no. 9, pp. 1795-1803, 2011.
71. F. Wang, N. Zhang, B. Li et al., "Heparin defends against the toxicity of circulating histones in sepsis," Frontiers in Bioscience, vol. 20, pp. 1259-1270, 2015.
72. J.Westman, E. Smeds, L. Johansson et al., "Treatment with p33 curtails morbidity and mortality in a histone-induced murine shockmodel," Journal of Innate Immunity, vol. 6, no. 6, pp. 819-830, 2014.